Blockbuster TOKYO "Accelerator Program" has supported over 50 entrepreneurs and teams since 2018. Participants who have given their consent to publish are listed on this page.
- Medical designers Inc.
- First Priority Co., Ltd.
- FiberMedicine Inc
- HikariQ Health Inc.
- JRAS inc.
- Techlico Inc.
- TXP Medical Co. Ltd.
- The team aiming to put drug discovery research results derived from Jichi Medical University to practical use.
- Shimane Univ
- GeroScience Research Institute
- THE PHAGE, Inc.
- Ovenus Lab
- R-NanoBio Co., Ltd.
Medical designers Inc.
日本では年間100万人ががんに罹患し40万人が亡くなる。がんは本人だけでなく親世代子世代にわたり悲しみと絶望をもたらし、社会を支える就労世代の罹患・死亡は社会にも大きな損失を与える。治らない患者さんは治るための治療を強く求めるがその情報がない。また、がんの治療はがんの種類と進行度によって定型的に決められた標準治療のみが提示されるため、治る患者さんであっても自分の価値観や体調にあった治療情報への訴求は大きい。 メディカルデザイナーズ社は個別に治療戦略を策定し、カスタマイズされた最適・有用な治療情報を提供し、根治（治る）確率の最大化と、納得感のある治療の実現を後押しする。 病状の見える化（精緻な病状把握）アルゴリズム、広範かつ最新の治療情報データベース（知恵の自己進化・名医の暗黙知等）などにより、診療情報のインプットで複数の治療戦略と治療情報をアウトプットする。
First Priority Co., Ltd.
We aim to create a society where individuals can share health information across the boundaries of medical institutions by comprehensively holding their own medical records using the PHR app. Furthermore, we will reduce medical costs by improving the efficiency of health management and eliminating duplication and waste of medical care. We are planning to develop a system that picks up waste and duplication that cannot be picked up by the current receipt examination in the secondary development of PHR and returns it to the health association by analysis using AI. By discovering the relationship between actual diseases and lifestyles from the big data collected, and providing tailor-made preventive measures from the clinical practice guidelines read by AI, we aim to improve health and recommend hospital visits in the future. , I would like to include a diagnostic support function, etc. In addition, by clearly expressing an individual's living will as a function of PHR, we can reduce the respect for individuals and waste of medical expenses, and we believe that we can have synergies with life insurance company products.
[Patient with inflammatory bowel disease repeatedly inspect their own saliva to maintain their health condition] In order to realize this ideal, we Fiber Medicine Inc, was established with the aim of developing medical devices from the advanced technology of the Faculty of Dentistry in Tohoku University. Inflammatory bowel disease (IBD) is an orphan disease that require long term treatment and repeat relapse and remission state. In addition to the classical diagnosis test including blood, stool urinalysis and endoscopy, we perform saliva test to investigate the biomarker for sign of relapse to develop immunochromatography test kit for early detection of IBD. We would like to establish this technology as a patient friendly saliva test kit and develop medical device that anyone can easily and repeatedly carry out to do early diagnosis of relapse for preventing exacerbation of IBD.
HikariQ Health Inc.
Our business is a development of First-in-class product by antibody engineering technology “Coiled Q-body” for antibody-drug conjugate. "Coiled Q-body" is a technology that can be expected to improve the efficacy and safety of ADCs (Antibody Drug Conjugates), which will become the mainstream of anticancer drugs in the future. “Coiled Q-body type ADC” devised by our company encloses an anticancer drug in an antibody, releases the encapsulation (the drug and antibody are still bound by a linker) when it binds to an antigen on the surface of the cancer cell, and releases the drug for the first time when it is taken into the cell. We expect that this technology will solve the problem of existing ADCs, which release anticancer drugs with large side effects during delivery. “Coiled Q-body type ADC” is still in the research and development stage, but because basic research has been completed as an application to immunoassay, we believe that the theory can also be applied to ADC.
JRAS inc. was established as a venture company originating from Kobe University with the aim of providing strong backup for work required in research and surveys at universities, research institutions, as well as medical institutions. In recent years, research activities have tended to require speedy results, and the content of research has become increasingly sophisticated. Under these circumstances, researchers are constantly thinking and worrying about how to continue to deliver high-quality results to the world in a timely manner. Therefore, our company is committed to helping research activities in Japan move forward, even if only a little, by providing support from advanced analysis using AI to simple tasks, with our Ph.D. qualified staff.
In this project, we develop "cognitive function DTx (Digital Therapeutics) using mixed reality technology". The cognitive dysfunction (memory and attention functions) can be an aftereffect of a disease such as stroke or MCI(pre-stage of dementia). We develop DTx for the treatment of this cognitive dysfunction, and for this we use MR (Mixed Reality) that advanced VR (Virtual Reality) as a seed technology. In the future, we aim to commercialize it as a DTx prescribed by doctors, collaborating with pharmaceutical companies. Currently, while conducting joint research with Kyoto University and Kansai Medical University, we are developing a medical device that utilizes the presentation of cognitive tasks using MR, and we are developing it as "Rehamaru" in a clinical site of rehabilitation. The effectiveness of "Rehamaru" has been confirmed, and it has been gathering attention because of presentation at academic conferences and papers.
TXP Medical Co. Ltd.
TXP Medical is a company established in August 2017 by Dr. Sonoo, an emergency physician and CEO, to solve problems in emergency medicine through systems. [Emergency Medical System "NEXT Stage ER"] We realize the digitization of the emergency medical scene through our main product, "NEXT Stage ER". By improving both the efficiency of operations and information collection at emergency medical sites, which are under pressure, we have gained customers in large hospitals and university hospitals that receive a large number of ambulances, which support emergency medical services in Japan. [Acute phase clinical trial support service "NEXT Stage Clinical Trial] From June 2021, we will provide the "NEXT Stage Clinical Trial" service for acute stage clinical trials. The service will provide support from two perspectives, "feasibility research" and "recruitment," for recruiting patients for acute stage clinical trials, which had been difficult due to time constraints. This will improve the speed of patient accumulation. [Medical Data Business] By digitizing the emergency medical scene, which has not been possible in the past, we acquire data that transcends facilities and organizations, and provide opportunities for data utilization. We are planning to develop and provide various medical data businesses in the future.
The team aiming to put drug discovery research results derived from Jichi Medical University to practical use.
Our goal is to develop therapeutic drugs for mitochondrial diseases and hemophilia. Prof. Hitoshi Osaka et al. have found that apomorphine has cell protective effect from ROS and improves mitochondrial respiratory activity in Leigh syndrome and MELAS patients’ fibroblasts. We are now to proceed to a pre-clinical trial of apomorphine targeting mitochondrial disease (Leigh encephalopathy). This pre-clinical trial is supported by AMED grant. Apomorphine, a short-acting D1- and D2-like receptor agonist, is used to treat “off” episodes in patients with advanced Parkinson’s disease. But, it has dopaminergic side effects such as nausea, somnolence and hypotonia. Currently, we found drug candidates having no dopamine agonist activity targeting mitochondrial diseases, and are preparing for patent application. Another therapeutic drug candidate is "modified Factor VIII" for gene therapy of hemophilia A. The patent application is currently under preparation. There are three problems on AAV gene therapy. Those are (1) limited target organs (central nervous system and liver), (2) infection inhibition due to the presence of anti-AAV neutralizing antibodies, and (3) liver damage during high-dose administration. To meet these challenges, we want to supply solutions such as novel drug delivery systems.
Development of therapeutic agents andcompanion diagnostics for schizophrenia subpopulation with a clear pathogenesis
GeroScience Research Institute
“Light suppers make long life” is a well known secret to a long and healthy life. The mechanism of the life-extending effects of calorie restriction has been studied for a long time. We developed the bioassay system to screen the calorie restriction mimetic compounds. We apply this system to develop novel drugs for the treatment of rare disorders and age-associated metabolic diseases. We have a pipeline of novel, first-in-class or best-in-class drug candidates for the treatment of nonalcoholic steatohepatitis (NASH). Our mission is to develop the novel therapeutics for patients suffering from not only common metabolic disorders but also rare diseases.
THE PHAGE, Inc.
The pressure on medical costs caused by diabetes is a global social issue, but the rate at which patients are able to improve their lifestyle has yet to be fully examined. As a solution to this problem, we are developing a therapeutic APP that uses a proprietary algorithm to score each user's blood glucose data per meal, and uses the accumulated data to encourage optimal dietary choices. Through the use of the APP, we expect to be able to create a future in which people can face diabetes through behavioral change from passive dietary guidance to proactive dietary choices.
"Women's healthcare starting with the egg" Ovaries are the organs responsible for women's health and reproduction. We develops a drug discovery business specializing in ovarian regeneration, which links women's health to the vitality of our society. 1. Develop a therapeutic drug that rejuvenates the ovaries By providing medical care that enables women to conceive when they want and to age healthily, we support women's shining way of life. 2. Develop a diagnostic test kit to assess regenerative potential of the ovaries For your life planning, we offer diagnostics product to measure the biological age of the ovaries.
We are building a medical service that allows many psychiatrists / patients to provide / enjoy optimal treatment through the “Precision Medical in the Treatment of Psychiatry and Neurological Disorders”. In the treatment of neuropsychiatric disorders, it is not easy for doctors in hospitals and clinics who do not have advanced testing facilities to select the optimal treatment policy for each patient. Even if there is a good treatment method, there are many cases in which a sufficient treatment response rate has not been achieved at present. In view of such a medical environment, we are developing diagnostic / therapeutic indexes for neuropsychiatric disorders using our unique analytical technology using AI. In the treatment of psychiatric disorders, even if doctors do not have advanced examination and analytical techniques, this index can be used to enable them selection of patient-optimized treatment policies and improve treatment outcomes. We will start with depression, which has the largest number of patients, and gradually expand the target scope.
R-NanoBio Co., Ltd.
Currently, there are few tests in clinical practice, and patients take blood samples after interviewing, and the blood is sent to the analysis center. Patients have to go to the hospital many times and remain anxious by the time the diagnosis is made. For medical professionals, it may be too late to make an early diagnosis. Until now, POCT has been a method of immunochromatography with a single item. Here we have succeeded in developing a system that can quantitatively test multiple items of blood sampled from fingertip "on the site". Currently, it is clinically applied in the field of allergy diagnosis. In the future, this system can be expected to contribute to on-site medical institutions, home medical care, telemedicine, and even disaster medical care where it becomes difficult to send supplies.